Premium
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
Author(s) -
Thompson D.D.,
Seedor J.G.,
Quartuccio H.,
Solomon H.,
Fioravanti C.,
Davidson J.,
Klein H.,
Jackson R.,
Clair J.,
Frankenfield D.,
Brown E.,
Simmons H.A.,
Rodan G.A.
Publication year - 1992
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650070812
Subject(s) - ovariectomized rat , bisphosphonate , etidronic acid , medicine , bone density conservation agents , alendronic acid , osteoporosis , diphosphonates , bone remodeling , endocrinology , bone density , bone resorption , estrogen
We examined the effect of the amino bisphosphonate alendronate, administered IV every 2 weeks at 0.05 and 0.25 mg/kg for 1 year, on bone loss and parameters related to bone metabolism in ovariectomized baboons. Relative to non‐OVX animals, the OVX baboons experienced increased bone turnover, reflected in biochemical and histomorphometric measurements, and bone loss assessed by dual‐beam absorptiometry in the lumbar spine, which was similar to changes observed in ovariectomized women. Alendronate treatment maintained all parameters of bone turnover at control (nonovariectomized) levels and prevented the bone loss in a dose‐dependent manner. We concluded that ovariectomized baboons offer a suitable model for the bone changes observed in ovariectomized women and that these changes can be prevented by sustained administration of an appropriate dose of this aminobisphosphonate.